TNXP Strangle Strategy
TNXP (Tonix Pharmaceuticals Holding Corp.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome.
TNXP (Tonix Pharmaceuticals Holding Corp.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $210.7M, a beta of 1.68 versus the broader market, a 52-week range of 10.03-69.97, average daily share volume of 481K, a public-listing history dating back to 2012, approximately 81 full-time employees. These structural characteristics shape how TNXP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.68 indicates TNXP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on TNXP?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current TNXP snapshot
As of June 30, 2026, spot at $12.79, ATM IV 102.50%, IV rank 28.04%, expected move 29.39%. The strangle on TNXP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on TNXP specifically: TNXP IV at 102.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a TNXP strangle, with a market-implied 1-standard-deviation move of approximately 29.39% (roughly $3.76 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TNXP expiries trade a higher absolute premium for lower per-day decay. Position sizing on TNXP should anchor to the underlying notional of $12.79 per share and to the trader's directional view on TNXP stock.
TNXP strangle setup
The TNXP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TNXP near $12.79, the first option leg uses a $13.43 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TNXP chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TNXP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $13.43 | N/A |
| Buy 1 | Put | $12.15 | N/A |
TNXP strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
TNXP strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on TNXP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on TNXP
Strangles on TNXP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TNXP chain.
TNXP thesis for this strangle
The market-implied 1-standard-deviation range for TNXP extends from approximately $9.03 on the downside to $16.55 on the upside. A TNXP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TNXP IV rank near 28.04% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TNXP at 102.50%. As a Healthcare name, TNXP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TNXP-specific events.
TNXP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TNXP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TNXP alongside the broader basket even when TNXP-specific fundamentals are unchanged. Always rebuild the position from current TNXP chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on TNXP?
- A strangle on TNXP is the strangle strategy applied to TNXP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TNXP stock trading near $12.79, the strikes shown on this page are snapped to the nearest listed TNXP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TNXP strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TNXP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 102.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TNXP strangle?
- The breakeven for the TNXP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TNXP market-implied 1-standard-deviation expected move is approximately 29.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on TNXP?
- Strangles on TNXP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TNXP chain.
- How does current TNXP implied volatility affect this strangle?
- TNXP ATM IV is at 102.50% with IV rank near 28.04%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.